Health Canada has released a revised labeling information for acetylsalicylic acid (ASA) products for use in adults and children of ages 12 years and older.
The information will enable people of Canada to choose the right pain or fever relief products for their needs, and use them more safely.
According to Health Canada, the updated information comprises clear warnings and ‘DO NOT’ cautionary statements that should be visible on package labels, inner panels and inserts.
The labeling standard should also include information on side effects of ASA products as well as information on when to doctor or pharmacist.
As per Health Canada’s updated labeling information, the required statements include cautions designed to help prevent overdose, as well as warnings for pregnant women, breastfeeding mothers and children, including a statement to help prevent the occurrence of Reye’s syndrome in children.
All acetylsalicylic acid products will be required to provide warning information on their outer and inner labels, including Codeine or caffeine warnings for nursing mothers.
Labeling standards outline information such as dose, intended use, directions for use, warnings, and active ingredients that companies should include on their product labels and packaging.